Galectin-3 Regulates Atrial Fibrillation Remodeling and Predicts Catheter Ablation Outcomes
Atrial fibrillation (AF) usually starts as paroxysmal but can evolve relentlessly to the persistent and permanent forms. However, the mechanisms governing such a transition are unknown. The authors show that intracardiac serum levels of galectin (Gal)-3 are greater in patients with persistent than p...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Elsevier
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979747/ |
| id |
pubmed-4979747 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-49797472016-08-22 Galectin-3 Regulates Atrial Fibrillation Remodeling and Predicts Catheter Ablation Outcomes Takemoto, Yoshio Ramirez, Rafael J. Yokokawa, Miki Kaur, Kuljeet Ponce-Balbuena, Daniela Sinno, Mohamad C. Willis, B. Cicero Ghanbari, Hamid Ennis, Steven R. Guerrero-Serna, Guadalupe Henzi, Bettina C. Latchamsetty, Rakesh Ramos-Mondragon, Roberto Musa, Hassan Martins, Raphael P. Pandit, Sandeep V. Noujaim, Sami F. Crawford, Thomas Jongnarangsin, Krit Pelosi, Frank Bogun, Frank Chugh, Aman Berenfeld, Omer Morady, Fred Oral, Hakan Jalife, José PRE-CLINICAL RESEARCH Atrial fibrillation (AF) usually starts as paroxysmal but can evolve relentlessly to the persistent and permanent forms. However, the mechanisms governing such a transition are unknown. The authors show that intracardiac serum levels of galectin (Gal)-3 are greater in patients with persistent than paroxysmal AF and that Gal-3 independently predicts atrial tachyarrhythmia recurrences after a single ablation procedure. Using a sheep model of persistent AF the authors further demonstrate that upstream therapy targeting Gal-3 diminishes both electrical remodeling and fibrosis by impairing transforming growth factor beta–mediated signaling and reducing myofibroblast activation. Accordingly, Gal-3 inhibition therapy increases the probability of AF termination and reduces the overall burden of AF. Therefore the authors postulate that Gal-3 inhibition is a potential new upstream therapy to prevent AF progression. Elsevier 2016-04-25 /pmc/articles/PMC4979747/ /pubmed/27525318 http://dx.doi.org/10.1016/j.jacbts.2016.03.003 Text en © 2016 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Takemoto, Yoshio Ramirez, Rafael J. Yokokawa, Miki Kaur, Kuljeet Ponce-Balbuena, Daniela Sinno, Mohamad C. Willis, B. Cicero Ghanbari, Hamid Ennis, Steven R. Guerrero-Serna, Guadalupe Henzi, Bettina C. Latchamsetty, Rakesh Ramos-Mondragon, Roberto Musa, Hassan Martins, Raphael P. Pandit, Sandeep V. Noujaim, Sami F. Crawford, Thomas Jongnarangsin, Krit Pelosi, Frank Bogun, Frank Chugh, Aman Berenfeld, Omer Morady, Fred Oral, Hakan Jalife, José |
| spellingShingle |
Takemoto, Yoshio Ramirez, Rafael J. Yokokawa, Miki Kaur, Kuljeet Ponce-Balbuena, Daniela Sinno, Mohamad C. Willis, B. Cicero Ghanbari, Hamid Ennis, Steven R. Guerrero-Serna, Guadalupe Henzi, Bettina C. Latchamsetty, Rakesh Ramos-Mondragon, Roberto Musa, Hassan Martins, Raphael P. Pandit, Sandeep V. Noujaim, Sami F. Crawford, Thomas Jongnarangsin, Krit Pelosi, Frank Bogun, Frank Chugh, Aman Berenfeld, Omer Morady, Fred Oral, Hakan Jalife, José Galectin-3 Regulates Atrial Fibrillation Remodeling and Predicts Catheter Ablation Outcomes |
| author_facet |
Takemoto, Yoshio Ramirez, Rafael J. Yokokawa, Miki Kaur, Kuljeet Ponce-Balbuena, Daniela Sinno, Mohamad C. Willis, B. Cicero Ghanbari, Hamid Ennis, Steven R. Guerrero-Serna, Guadalupe Henzi, Bettina C. Latchamsetty, Rakesh Ramos-Mondragon, Roberto Musa, Hassan Martins, Raphael P. Pandit, Sandeep V. Noujaim, Sami F. Crawford, Thomas Jongnarangsin, Krit Pelosi, Frank Bogun, Frank Chugh, Aman Berenfeld, Omer Morady, Fred Oral, Hakan Jalife, José |
| author_sort |
Takemoto, Yoshio |
| title |
Galectin-3 Regulates Atrial Fibrillation Remodeling and Predicts Catheter Ablation Outcomes |
| title_short |
Galectin-3 Regulates Atrial Fibrillation Remodeling and Predicts Catheter Ablation Outcomes |
| title_full |
Galectin-3 Regulates Atrial Fibrillation Remodeling and Predicts Catheter Ablation Outcomes |
| title_fullStr |
Galectin-3 Regulates Atrial Fibrillation Remodeling and Predicts Catheter Ablation Outcomes |
| title_full_unstemmed |
Galectin-3 Regulates Atrial Fibrillation Remodeling and Predicts Catheter Ablation Outcomes |
| title_sort |
galectin-3 regulates atrial fibrillation remodeling and predicts catheter ablation outcomes |
| description |
Atrial fibrillation (AF) usually starts as paroxysmal but can evolve relentlessly to the persistent and permanent forms. However, the mechanisms governing such a transition are unknown. The authors show that intracardiac serum levels of galectin (Gal)-3 are greater in patients with persistent than paroxysmal AF and that Gal-3 independently predicts atrial tachyarrhythmia recurrences after a single ablation procedure. Using a sheep model of persistent AF the authors further demonstrate that upstream therapy targeting Gal-3 diminishes both electrical remodeling and fibrosis by impairing transforming growth factor beta–mediated signaling and reducing myofibroblast activation. Accordingly, Gal-3 inhibition therapy increases the probability of AF termination and reduces the overall burden of AF. Therefore the authors postulate that Gal-3 inhibition is a potential new upstream therapy to prevent AF progression. |
| publisher |
Elsevier |
| publishDate |
2016 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979747/ |
| _version_ |
1613624976257056768 |